Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma

PURPOSE: Effective biomarkers for malignant mesothelioma (MM) are needed for clinical management and the development of mesothelin-targeted therapies. We evaluated serum megakaryocyte potentiating factor (MPF) as a biomarker predictive of treatment outcome in patients with MM and for developing meso...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Precis Oncol
Autors principals: Cao, Liang, Yu, Yunkai, Thomas, Anish, Zhang, Jingli, Onda, Masanori, Meltzer, Paul, Hassan, Raffit, Pastan, Ira
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2018
Matèries:
Original Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201260/
https://ncbi.nlm.nih.gov/pubmed/30370397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00282
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars